The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
JHEP Rep. 2020 Oct;2(5):100169. doi: 10.1016/j.jhepr.2020.100169.Epub 2020 Aug 4.
Tobias Boettler1, Thomas Marjot2, Philip N Newsome34, Mario U Mondelli5, Mojca Maticic67, Elisa Cordero8, Rajiv Jalan9, Richard Moreau1011, Markus Cornberg1213, Thomas Berg14
Author information
1Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
2Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, UK.
3National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
5Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
6Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia.
7Faculty of Medicine, University of Ljubljana, Slovenia.
8Department of Medicine, University of Seville, Clinical Unit of Infectious Diseases University Hospital Virgen del Rocio, Institute of Biomedicine, Sevilla, CSIC, Spain.
9Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, UK.
10Inserm, Université de Paris, U1149, Centre de Recherche sur l'Inflammation (CRI), UMRS1149, Paris, France.
11Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France.
12Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
13Centre for Individualised Infection Medicine (CIIM), Hannover, Germany.
14Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Abstract
During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare systems are returning to a more normal routine, many countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is significantly impacting on the care of these patients. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the disease course must be kept in mind when caring for patients with COVID-19. This review should serve as an update on the previous position paper, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.